Keros Therapeutics, Inc.
KROS
$10.10
-$0.56-5.25%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
8/15/2026
-
Tickeron - Stocks
8/14/2026
-
Insider Monkey
8/13/2026
-
Tickeron - Stocks
8/13/2026
-
MarketBeat
8/11/2026
-
TipRanks
8/11/2026
-
TipRanks: TheFly
8/10/2026
-
MarketBeat
8/8/2026
-
MarketBeat
8/7/2026
-
MarketBeat
8/7/2026
-
Tickeron - Stocks
8/7/2026
-
Tickeron - Stocks
8/6/2026
-
MarketBeat
8/4/2026
-
Zacks Investment Research
8/4/2026
-
TipRanks
8/4/2026
-
TipRanks
8/4/2026
-
MarketBeat
8/4/2026
-
TipRanks
8/4/2026
-
TipRanks: TheFly
8/4/2026
-
TipRanks: TheFly
8/4/2026
-
TipRanks
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS
8/3/2026
-
MarketBeat
8/3/2026
-
Globe Newswire
8/3/2026
-
MarketBeat
7/30/2026
-
TipRanks
7/30/2026
-
Globe Newswire
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, August 3, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 2 and 6 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 314 6297
Address
1050 Waltham Street
Suite 302
Lexington, MA 02421
Suite 302
Lexington, MA 02421
Country
Year Founded
Business Description
Sector
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the...
more